Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Dibutylamine | HCID 8148 | — |
| Reactant | HCID 54112781 | HCID 54112781 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 54498054 | HCID 54498054 | 84% |
Reaction Steps
0.6 ml (3.45 mmol) of dibutylamine was added to a suspension of 400 mg (1.15 mmol) of (S)-1-(5-chloromethyl-1,2,4-oxadiazol-3-yl)-11,11a-dihydro-8H,10H-azeto[1,2-a]imidazo[5,1-c]thieno[3,2-e]-[1,4]diazepin-8-one in 10 ml of N,N-dimethylformamide and the mixture was stirred at room temperature for 12 hours. The solution was evaporated and the residue was partitioned between methylene chloride and 2N sodium carbonate solution. The aqueous solution was extracted with methylene chloride and the organic phases were dried with magnesium sulfate, filtered and evaporated. The residue was chromatographed (silica gel, methyl acetate/methanol 10:1). There were obtained 425 mg (84%) of (S)-1-(5-dibutylaminomethyl-1,2,4-oxadiazol-3-yl)-11,11a-dihydro-8H,10H-azeto[1,2-a]imidazo[5,1-c]thieno[3,2-e][1,4]diazepin-8-one as a colourless foam, Rf=0.31 (silica gel, methyl acetate/methanol 10:1).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US05665718 |
|---|
| Source dataset | uspto-grants-1997_09 |
|---|
| ORD ID | ord-ebc6f3eb24fe40b1bb220279d71f7859 |
|---|
| Source note | uspto-grants-1997_09 |
|---|